Targeting Hypoglossal Neurobiology in the Treatment of Obstructive Sleep Apnea: The Emergence of Aroxybutynin–Atomoxetine (AD109)

Stanley Wong, Tetyana Kendzerska, Michael S. B. Mak · 2026

Read Targeting Hypoglossal Neurobiology in the Treatment of Obstructive Sleep Apnea: The Emergence of Aroxybutynin–Atomoxetine (AD109) by Stanley Wong, Tetyana Kendzerska, Michael S. B. Mak (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13511467.txt.

Description

Wong, Kendzerska, and Mak reviewed in 2026 a nightly pill for obstructive sleep apnea, a disorder where the throat closes repeatedly during sleep. Air pressure masks are the standard cure but many patients cannot tolerate them. The pill, called AD109, pairs atomoxetine with aroxybutynin. During sleep, nerve drive to the tongue muscle fades and a braking signal rises, so the targeted pair aims to restore throat muscle tone at its root in the brainstem.

Wong reports two large phase 3 trials in adults who refused or could not use air pressure therapy. After 26 weeks, the pill cut the hourly count of breathing pauses and shallow breaths by roughly 44 to 47 percent more than placebo, and night oxygen levels improved. Side effects were mostly dry mouth, poor sleep, nausea, and hesitant urination, with no serious treatment-linked events. Longer data and direct comparison with masks are still needed.

Catalog record

CREATORStanley Wong, Tetyana Kendzerska, Michael S. B. Mak
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13511467

Browse the full library · About the Tower of Babel